TEVA | tickerfilter.com

Fundamental analysis

38%

Profitability 21%

Dept financing 43%

Liquidity 26%

Performance 56%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-5.98%

1 Month

-8.48%

3 Months

12.07%

6 Months

64.51%

1 Year

106.84%

2 Year

134.66%

Key data

Stock price

$31.75

P/E Ratio

25.39

DAY RANGE

$31.24 - $32.35

EPS

$1.23

52 WEEK RANGE

$12.46 - $37.34

52 WEEK CHANGE

$106.71

MARKET CAP

35.807 B

YIELD

N/A

SHARES OUTSTANDING

1.150 B

DIVIDEND

$0.085

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

07-30-2025

BETA

0.25

PUBLIC FLOAT

AVERAGE 10 VOLUME

$7,085,527

AVERAGE 30 VOLUME

$7,311,934

Company detail

CEO: Kåre Schultz
Region: US
Website: tevapharm.com
Employees: 36,800
IPO year: 1990

Issue type: American Depository Receipt (ADR’s)
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Teva Pharmaceutical Industries Limited sells generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. Its products in the central nervous system, pain, respiratory, and oncology areas include Copaxone for the treatment of relapsing forms of multiple sclerosis. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

TEVA - TEVA PHARMACEUTICAL INDUSTRIES LTD